Drugs / pTTL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05908643 | Mar 2023 → Dec 2027 expected | colorectal cancer | Neogap Therapeutics AB | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pTTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05908643 ↗ |
| Modality | Cell therapy | “autologous cell product for adoptive cancer immunotherapy” NCT05908643 ↗ |
| Route | Intravenous | “intended for intravenous transfusion” NCT05908643 ↗ |